MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why GELS Stock surged +5.11% Today — RQD Quant Desk Flash
$0.51 +5.11% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.51
Gelteq Limited (GELS) carries a Roarable Rating of C- (Hold) with 59/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
ROARABLE C- • HOLD / WATCH
Cap $5.4M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.51 (+0.73%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 59/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.2% avg 90D alpha vs SPY • 53.1% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERHOLD / WATCH • C-
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw C- · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE+0% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GELS)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (59/100 Composite)
🔍 WHY GELS SCORES 59/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+15/20 pts (25% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (22% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)
Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade B-$0.52-13.5% Next Q
67
Q2 (-2Q)Grade C+$0.45-4.4% Next Q
64
Q3 (-1Q)Grade C+$0.43+18.6% Next Q
62
CurrentGrade C-$0.51+0.2% Hist 90D α
59
Trajectory: B- (67) → C- (59)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the GELS Bull Thesis Could Fail
Even with a 59/100 (C-) score, GELS faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Company executives have done more routine share selling than personal cash buying lately.
⚠️ Forensic Kill-Switch #2
Sensitive to high interest rates and tighter Federal Reserve market liquidity.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($0.56) or 200D SMA ($0.66) invalidates the momentum regime and cuts Target Base ($0.51) toward Bear Floor ($0.40).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $GELS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “GELS Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why GELS Stock surged +5.11% Today — RQD Quant Desk Flash
Gelteq Limited (GELS) surged +5.11% to $0.51, trading at 7% of its 52-week range ($0.39 – $2.01). Solid steady margins (steady margins), mixed timing at current multiples—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 7% of its 52-week range ($0.39 – $2.01) with RSI-14 at 48.2 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.51 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable C- (Hold) backed by 52% gross margin and $151754 annual free cash flow.
Live GELS Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (GELS Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
GELS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -20.31%⚡ TESTING RESISTANCE
2026-10-30O $0.48H $0.51L $0.45C $0.51VOL 26.2K
RES: $0.53SUP: $0.43SMA50: $0.56SMA200: $0.66
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
GELS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on GELS today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for GELS. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for GELS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GELS)
Health Care Rank #217 of 1016
⚔️ BGMS vs GELS Full Matrix →
1. Head-to-Head Health Care Peer Comparison (GELS vs. BGMS, PCSA, LGVN, PULM)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Gelteq Limited (GELS) ranks #217 by composite RQD confidence (59/100, grade C-) and #938 by equity capitalization ($5.4M). Within this direct 5-issuer industry benchmark cohort, GELS leads on earnings valuation at N/A trailing P/E, while BGMS leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. GELS currently leads its immediate peer cohort in composite quantitative strength at 59/100 (C-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| GELS
ACTIVE
Gelteq Limited | C- | 59/100 | — | — | — | +5.11% | $5.4M | Benchmark Subject |
| BGMS Bio Green Med Solution Inc. | D- | 40/100 | — | — | -35.0% | -9.79% | $5.5M | /bgms-vs-gels → |
| PCSA Processa Pharmaceuticals Inc. | D | 48/100 | — | — | -35.0% | +2.16% | $5.3M | /pcsa-vs-gels → |
| LGVN Longeveron Inc. (Class A) | E | 32/100 | — | 67.0% | -35.0% | -1.68% | $5.6M | /lgvn-vs-gels → |
| PULM Pulmatrix Inc. | D- | 36/100 | — | — | -35.0% | -5.67% | $5.2M | /pulm-vs-gels → |
2. GELS Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics
TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOTGelteq Limited (GELS) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $5.4M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
3. GELS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs GELS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Gelteq Limited (NASDAQ: GELS) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 59/100 at a spot price of $0.51 (+5.11% 1D, market cap $5.4M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, GELS ranks #217 in composite RQD confidence.
How does GELS compare to BGMS and PCSA in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GELS carries a Roarable C- (59/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, BGMS (Bio Green Med Solution Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $5.5M) and PCSA (Processa Pharmaceuticals Inc.) posts a D grade (48/100 RQD, P/E N/A, ROIC -35.0%, cap $5.3M). Among the 5-stock peer group, GELS leads on earnings multiple (N/A) while BGMS leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for GELS?
For Gelteq Limited (GELS), key quantitative strengths include Big institutional funds and options desks are actively positioning on the bullish side. and sector rank #217 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is GELS trading relative to its 50-day, 200-day, and 52-week technical levels?
GELS last traded at $0.51 (+5.11% on volume of 77,208 shares), positioning the stock -8.93% below its 50-day simple moving average ($0.56) and -22.73% below its 200-day simple moving average ($0.66). Across its 52-week range of $0.39 to $2.01, GELS sits at the 7.4% percentile with a 14-day RSI of 48.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.57).
GELS Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is GELS stock moving today?
Why GELS Stock surged +5.11% Today — RQD Quant Desk Flash. Solid steady margins (steady margins), mixed timing at current multiples—hold if owned, no rush to chase.